×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IFRX – inflarx n.v. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IFRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/15
07:54 am
ifrx
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome [Yahoo! Finance]
Low
Report
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome [Yahoo! Finance]
11/15
07:51 am
ifrx
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
High
Report
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
11/13
02:07 am
ifrx
InflaRx Reports Q3 2024 Financial Results and Progress [Yahoo! Finance]
Medium
Report
InflaRx Reports Q3 2024 Financial Results and Progress [Yahoo! Finance]
11/11
10:22 am
ifrx
InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Medium
Report
InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
11/8
07:30 am
ifrx
InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update
10/31
07:30 am
ifrx
InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference
Low
Report
InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference
9/25
02:04 pm
ifrx
InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Low
Report
InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
9/25
07:30 am
ifrx
InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress
Low
Report
InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/31
InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx’s anti-C5a Technology
50.0%
4/29 Form 20-F InflaRx N.V. For: Dec 31 30.0%
2/14 Form SC 13G/A InflaRx N.V. Filed by: Cormorant Asset Management, LP 23.6%
2/19 InflaRx to Present at Upcoming SVB Leerink Global Healthcare Conference 14.9%
2/26 Form 6-K InflaRx N.V. For: Feb 26 14.1%
6/12 Inflarx NV (NASDAQ: IFRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.75 price target on the stock. 6.1%
1/8 Inflarx NV (NASDAQ: IFRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.00 price target on the stock. 5.2%
10/23 Inflarx NV (NASDAQ: IFRX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 4.9%
6/14 Form 6-K InflaRx N.V. For: Jun 14 4.7%
6/13 InflaRx Treats First Patient in Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum 3.6%
4/29 Form 20-F InflaRx N.V. For: Dec 31 30.0%
2/14 Form SC 13G/A InflaRx N.V. Filed by: Cormorant Asset Management, LP 23.6%
2/19 InflaRx to Present at Upcoming SVB Leerink Global Healthcare Conference 14.9%
2/26 Form 6-K InflaRx N.V. For: Feb 26 14.1%
6/12 Inflarx NV (NASDAQ: IFRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.75 price target on the stock. 6.1%
1/8 Inflarx NV (NASDAQ: IFRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.00 price target on the stock. 5.2%
10/23 Inflarx NV (NASDAQ: IFRX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 4.9%
6/14 Form 6-K InflaRx N.V. For: Jun 14 4.7%
6/13 InflaRx Treats First Patient in Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum 3.6%
TOP News Decliners
6/5
Form 6-K InflaRx N.V. For: Jun 05
-91.8%
4/1 Form 6-K InflaRx N.V. For: Mar 31 -34.4%
3/2 Form 6-K InflaRx N.V. For: Mar 02 -23.5%
11/7 Form 6-K InflaRx N.V. For: Nov 07 -21.7%
7/18 Form 6-K InflaRx N.V. For: Jul 18 -16.0%
5/23 Form 6-K InflaRx N.V. For: May 23 -10.2%
4/29 InflaRx Reports Full Year 2019 Financial & Operating Results -7.8%
11/14 Form 6-K InflaRx N.V. For: Nov 14 -5.3%
4/9 Form 6-K InflaRx N.V. For: Apr 09 -3.1%
2/26 InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum -3.0%
4/1 Form 6-K InflaRx N.V. For: Mar 31 -34.4%
3/2 Form 6-K InflaRx N.V. For: Mar 02 -23.5%
11/7 Form 6-K InflaRx N.V. For: Nov 07 -21.7%
7/18 Form 6-K InflaRx N.V. For: Jul 18 -16.0%
5/23 Form 6-K InflaRx N.V. For: May 23 -10.2%
4/29 InflaRx Reports Full Year 2019 Financial & Operating Results -7.8%
11/14 Form 6-K InflaRx N.V. For: Nov 14 -5.3%
4/9 Form 6-K InflaRx N.V. For: Apr 09 -3.1%
2/26 InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum -3.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: